Related Experiment Video
Updated: Jan 13, 2026
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Assessing the Impact of Colchicine on Pulmonary Fibrosis Using Imaging in Patients With Moderate-to-Severe COVID-19
Gulhan Ayhan Albayrak1, Mustafa Ilteris Bardakci1, Ugur Temel2
1Pulmonology Department, Şişli Hamidiye Etfal Training and Research Hospital, University of Health Sciences Turkey, İstanbul, Turkey, akdeniz.edu.tr.
Objective:
Pulmonary fibrosis may develop in patients with severe clinical conditions, especially those with high inflammatory indicators. We aimed to investigate the 15-month follow-up clinical outcomes in patients with moderate-to-severe COVID-19 pneumonia treated with colchicine and to evaluate its potential in preventing post-COVID pulmonary fibrosis.
Method:
This study, beginning with a retrospective analysis of 1489 selected patients, and a follow-up assessment of 155 patients conducted 15 months after hospital discharge. This study included 90 patients presenting with COVID-19 pneumonia with severity ranging from moderate to severe who were treated with colchicine alongside standard care, and 65 patients who did not receive colchicine were included in the control group to serve as a comparator. Patients who received colchicine treatment were included in Group 1, and those that did not in Group 2.
Results:
From admission to the 15-month follow-up, patients receiving colchicine exhibited a significant regression in chest CT abnormalities when compared with the control group (p < 0.05). Additionally, 65.6% (n = 59) of the colchicine group experienced symptomatic improvement, significantly higher than 35.4% (n = 23) in the control group (p < 0.05). Ninety patients who received colchicine treatment had Stage 3, 4, or 5, and only 28 had Stage 3, 4, or 5 pulmonary fıbrosis at the end of 15 months. After 15 months of follow-up, all 20 patients initially classified as Stage 5 who received colchicine remained at Stage 5 pulmonary fibrosis, whereas in the control group, 2 patients (3.1%) were fibrosis-free, and the others presented with Stage 1 (n = 23; 35.4%), Stage 3 (n = 23; 35.4%), Stage 4 (n = 9; 13.8%), or Stage 5 (n = 8; 12.3%) pulmonary fibrosis.
Conclusion:
This study demonstrates that colchicine therapy might reduce pulmonary fibrosis progression in individuals affected by COVID-19 pneumonia. Clinicians should consider colchicine treatment to prevent pulmonary fibrosis.
More Related Videos
03:38Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models
Published on: June 20, 2025
07:38A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice
Published on: April 13, 2018
Related Concept Videos
01:20COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:22Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
01:29Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation